替尔泊肽全面超越司美格鲁肽,大约在明年

药智网
Aug 28

如果把诺和诺德与礼来的GLP-1药物之争看作一场足球比赛的话,那么2021—2025年就像是上半场的比赛,诺和诺德凭借更早的上市时间在势头上压制礼来的产品。但场上局势似乎将在以2026年为分界的下半场出现逆转。2026年,实现全面超越根据彭博社的预测,Mounjaro和Zepbound将在2026年全面超越Ozempic与Wegovy,并在接下来的三年显著拉大差距(图1)。图1 Wegovy,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10